Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2674 | YUKA1 | Selective inhibitor of KDM5A demethylase | €125.00 | |
| 3995 | WT-161 | Potent,selective,and bioavailable HDAC6 inhibitor | Inquire | |
| 2969 | WM-1119 | Highly potent and selective KAT6A inhibitor | €130.00 | |
| 2411 | WDR5-0103 | Inhibitor of WD40 repeat protein 5 (WDR5) and associated activity of H3K4 HMTase MLL | €90.00 | |
| 3114 | Vorinostat | HDAC inhibitor | €45.00 | |
| 3722 | Valemetostat | Inhibitor of Histone Lysine Methyltransferase EZH1/2 | €160.00 | |
| 3592 | UNC7145 | Negative control of UNC6934 as a chemical probe targeting NSD2-PWWP1 | €90.00 | |
| 3591 | UNC6934 | Potent and selective chemical probe targeting NSD2-PWWP1 | €120.00 | |
| 1840 | UNC0646 | Inhibitor of G9a/GLP Histone Lysine Methyltransferase | €99.00 | |
| 1889 | UNC0638 | Inhibitor of G9a (EHMT2)/GLP (EHMT1) | €85.00 | |
| 1841 | UNC0631 | Inhibitor of G9a/GLP Histone Lysine Methyltransferase | €99.00 | |
| 2418 | UNC0379 | Substrate competitive inhibitor of the H4K20 HMTase SETD8 | €125.00 | |
| 1789 | UNC0224 | Inhibitor of G9a HMTase | €85.00 | |
| 2518 | UF 010 | Class I selective HDAC inhibitor that inhibits cancer cell proliferation | €60.00 | |
| 2893 | Tucidinostat | Orally bioavailable HDAC inhibitor (1, 2, 3, 10 Selective) | €95.00 | |
| 2004 | Tubastatin A hydrochloride | Potent and selective HDAC6 inhibitor | €95.00 | |
| 3691 | Tubacin | HDAC6 inhibitor | Inquire | |
| 2180 | TMP 195 | HDAC inhibitor (class IIA selective) | €110.00 | |
| 2339 | TH 1834 | Tip60 histone acetyltransferase inhibitor | €140.00 | |
| 2249 | Tenovin 6 | Small water soluble p53 activator and SIRT inhibitor | €105.00 | |
| 2008 | Tenovin 1 | Activates p53 through inhibition of SIRT 1 and 2 | €70.00 | |
| 5008 | Stem Cell RG-BIX inhibitor Set | Set of RG 108 and BIX 01294 HCl, inhibitors of DNMT and HMTase, respectively | €60.00 | |
| 1875 | SRT 1720 tetrahydrochloride | Activator of the sirtuin subtype SIRT1 | €95.00 | |
| 4034 | SR-4370 | Synthetic inhibitor of histone deacetylase (HDAC) | Inquire | |
| 2864 | SP 2509 | Potent, reversible, and specific LSD1 inhibitor | €80.00 | |
| 2209 | Sodium butyrate | Noncompetitive inhibitor of multiple histone deacetylases (HDACs) | €50.00 | |
| 3908 | Sirtinol | Specific SIRT inhibitor | €90.00 | |
| 2968 | SIRT7 inhibitor 97491 | Inhibitor of SIRT7 | €135.00 | |
| 2453 | SirReal 2 | SIRT2 inhibitor with >1000 fold selectivity over SIRT1 and SIRT3 | €95.00 | |
| 3623 | SGC-SMARCA-BRDVIII | Potent, highly selective and cell-active SMARCA2/4 and PB1(5) bromodomain inhibitor | €90.00 | |